AC Immune partners with Lilly for Alzheimer's treatments in $1.9bn deal
Eli Lilly & Co. and AC Immune SA have joined forces in a new multi-year deal focused on tau aggregation inhibitors for Alzheimer’s disease and other neurodegenerative conditions.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.